Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Online CME Information
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gotfried, M. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gotfried, M. H.
(Chest. 2004;125:52S-61S.)
© 2004 American College of Chest Physicians

Macrolides for the Treatment of Chronic Sinusitis, Asthma, and COPD*

Mark H. Gotfried, MD, FCCP

* From the University of Arizona, Phoenix, AZ.

Correspondence to: Mark Gotfried, MD, FCCP, Pulmonary Associates, PA, 9225 N. Third St, Suite 200B, Phoenix, AZ 85020; e-mail: mgotfried{at}pol.net

In addition to their well-known antimicrobial activity, macrolides possess immunomodulatory properties that may confer beneficial effects to patients with respiratory diseases associated with chronic inflammation. These properties include attenuation of inflammatory responses in the lung, mucoregulatory properties, and effects on bronchial responsiveness. Macrolides increase mucociliary clearance, improve sinusitis symptoms, and decrease nasal secretions and polyp size in patients with sinusitis. They also have been shown to modify the inflammatory response associated with chronic sinusitis. In patients with asthma, macrolides have been reported to reduce airway hyperresponsiveness and improve pulmonary function, and have historically been selected for their "steroid-sparing" effect. Preliminary data from studies of patients with COPD have shown improvements in symptom scores and FEV1 after macrolide treatment. As biological response modifiers, macrolides have the potential to improve the outcomes of patients with inflammatory airway diseases. Large scale, placebo-controlled clinical trials designed to assess long-term efficacy and safety in these diseases are warranted.

Key Words: anti-inflammatory activity • asthma • clarithromycin • COPD • erythromycin • macrolides • roxithromycin • sinusitis




This article has been cited by other articles:


Home page
 Am. J. Respir. Crit. Care Med.Home page
S. L. Johnston and R. J. Martin
Chlamydophila pneumoniae and Mycoplasma pneumoniae: A Role in Asthma Pathogenesis?
Am. J. Respir. Crit. Care Med., November 1, 2005; 172(9): 1078 - 1089.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
B. Yates, D. M. Murphy, I. A. Forrest, C. Ward, R. M. Rutherford, A. J. Fisher, J. L. Lordan, J. H. Dark, and P. A. Corris
Azithromycin Reverses Airflow Obstruction in Established Bronchiolitis Obliterans Syndrome
Am. J. Respir. Crit. Care Med., September 15, 2005; 172(6): 772 - 775.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American College of Chest Physicians.